C6 Ceramide-d11

C6 Ceramide-d11 is deuterated labeled C6 Ceramide (HY-19542) . C6-ceramide, a ceramide pathway activator, shows activity against a variety of cancer cell lines. C6-ceramide can be used as an adjuvant for chemotherapeutic agents, to enhance anti-tumor effects[1][2].

Product Specifications

Product Name Alternative

C6-Cer-d11; N-Hexanoylsphingosine-d11

UNSPSC

12352211

Target

Apoptosis; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Solubility

10 mM in DMSO

Smiles

CCCCCCCCCCCCC/C=C/[C@](O)([H])[C@@]([H])(NC(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=O)CO

Molecular Formula

C24H36D11NO3

Molecular Weight

408.70

References & Citations

[1]Zhu Q, et, al. C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo. Cell Death Dis. 2011 Jan 27;2 (1) :e117. |[2]Liu L, et, al. C6-ceramide treatment inhibits the proangiogenic activity of multiple myeloma exosomes via the miR-29b/Akt pathway. J Transl Med. 2020 Aug 3;18 (1) :298. |[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.